Jiangxi Synergy Pharmaceutical

What Jiangxi Synergy Pharmaceutical does

Jiangxi Synergy Pharmaceutical is a China-headquartered specialty active pharmaceutical ingredient (API) manufacturer founded in 2004 and listed on the Shenzhen Stock Exchange ChiNext board (stock code: 300636) since March 2017. The company operates from Fengxin County, Jiangxi Province, with a workforce of more than 1,400 employees including over 200 R&D personnel, manufacturing APIs and intermediates at industrial scale across roughly 500 reactors totaling approximately 3 million liters of capacity. Its product portfolio spans mature high-volume molecules such as Gabapentin (1,800 t/yr), Aceclofenac, Rebamipide, and Celecoxib, alongside newer differentiated APIs including Ticagrelor, Rivaroxaban, Candesartan, Edoxaban Tosylate, Mersaartan Potassium, Vildagliptin, Mirabegron, and Vonoprazan Fumarate. The company also offers CMO/CDMO services and holds a national post-doctoral research workstation.

Synergy serves multinational pharmaceutical manufacturers across more than 50 countries, with Europe, the United States, Japan, and Korea accounting for over 60% of sales. It monetizes through API supply contracts, technology transfer, and contract development services, and earns incremental revenue from licensed patents (including US crisaborole rights) and from a growing domestic Chinese finished-dose business via CDE drug approvals. Its regulatory positioning is unusually broad for a mid-tier Chinese API producer: five consecutive US FDA cGMP inspections with No Action Indicated outcomes (2009, 2014, 2016, 2019, 2025), EU GMP, Japan PMDA, Korea MFDS, Brazil ANVISA, and EDQM CEP certifications across multiple products. R&D spend exceeds 6% of revenue, supporting eight process technology platforms that span heterocyclic synthesis, asymmetric catalysis, enzymatic chemistry, fluorination, and continuous flow.

The business model is anchored by long-cycle, qualification-based B2B supply relationships rather than transactional spot sales, with over 50 customer audits conducted annually reinforcing customer integration. Capacity is being expanded via a Phase 2 factory on 244,000 sqm of land and a 20,000 sqm R&D center that opened in September 2025, signaling a multi-year buildout intended to support both organic API growth and CDMO scale-up.

Name

Jiangxi Synergy Pharmaceutical

Legal name

江西同和药业股份有限公司

Website

https://jxsynergy.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Jiangxi Synergy Pharmaceutical is a Chinese specialty API manufacturer (Shenzhen-listed, 300636) that produces active pharmaceutical ingredients and intermediates for multinational drug companies across more than 50 countries, with regulatory certifications from FDA, EMA, PMDA, MFDS, and ANVISA, and is expanding capacity through a Phase 2 factory and new R&D center.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients (APIs)

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Small-Molecule API Commercial Manufacturing (HLAGAHAB), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Active pharmaceutical ingredients
• Pharmaceutical intermediates
• CMO CDMO services
• Specialty API manufacturing
• CGMP contract manufacturing

Headquarters

HQ city

Fengxin

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Active Pharmaceutical Ingredient (API) Manufacturing & Sales: The company manufactures and sells specialty active pharmaceutical ingredients (原料药) and pharmaceutical intermediates to global pharmaceutical companies. Products are exported to over 50 countries, with Europe, US, Japan, and Korea accounting for 60%+ of total sales. The company also provides CMO/CDMO contract manufacturing services.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Jiangxi Synergy Pharmaceutical manufactures specialty active pharmaceutical ingredients (APIs) and pharmaceutical intermediates for global pharmaceutical companies, with commercialized products spanning cardiovascular, CNS, diabetes, anti-inflammatory, and gastrointestinal therapeutic areas. The company operates a CMO/CDMO platform providing lab-to-commercial scale-up, process optimization, and regulatory registration support from its GMP-compliant facilities in Fengxin County, Jiangxi. Products are exported to over 50 countries, with Europe, the US, Japan, and Korea accounting for 60%+ of total sales.

Product overview

Jiangxi Synergy Pharmaceutical is a specialty chemical pharmaceutical company that manufactures active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company operates as a single unified production platform with core products being specialty generic APIs focused on therapeutic areas including cardiovascular disease, neurological disorders, gastrointestinal conditions, and diabetes. The product portfolio consists of commercialized APIs (Gabapentin, Rebamipide, Celecoxib, Ticagrelor, Rivaroxaban, Candesartan Cilexetil, Aceclofenac), new products in development pipeline (Canagliflozin, Mersaartan Potassium, Edoxaban Tosylate), and pharmaceutical intermediates for various drug molecules. The company also provides CMO/CDMO contract manufacturing services leveraging its GMP-compliant facilities and R&D capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Gabapentin (加巴喷丁) Anti-epileptic and analgesic API for treating epilepsy and neuropathic pain. Annual production capacity of 1,800 tons; production capacity and quality are leaders in China. EU EDQM CEP certified.
• Rebamipide (瑞巴派特) Gastrointestinal API for treatment of gastric ulcers, acute gastritis, and chronic gastritis. Annual production capacity of 200 tons. Recognized as Jiangxi Famous Brand Product.
• Celecoxib (塞来昔布) Anti-inflammatory analgesic API for osteoarthritis and rheumatoid arthritis symptom relief. Annual production capacity of 200 tons. EU CEP certified.
• Ticagrelor (替卡瑞洛) Anti-thrombotic API for cardiovascular disease treatment. Annual production capacity of 50 tons.
• Rivaroxaban (利伐沙班) Anti-thrombotic API used for venous thromboembolism prevention. Annual production capacity of 30 tons.
• Candesartan Cilexetil (坎地沙坦酯) Anti-hypertensive API used for treating high blood pressure. Annual production capacity of 20 tons.
• Aceclofenac (醋氯芬酸) Anti-inflammatory analgesic API. Annual production capacity of 150 tons.
• Canagliflozin (卡格列净) SGLT2 inhibitor API for Type 2 diabetes treatment. Recently received FDA approval.
• Pharmaceutical Intermediates (Rivaroxaban, Apixaban, Empagliflozin, Vonoprazan Fumarate, Edoxaban Tosylate) Specialty pharmaceutical intermediates supporting synthesis of anti-thrombotic, anticoagulant, antidiabetic, and gastric acid secretion inhibitor APIs, sold to API manufacturers globally.
• CMO/CDMO Contract Manufacturing Services Contract manufacturing and development services for pharmaceutical companies, covering laboratory process optimization, pilot scale-up, and commercial production from GMP-compliant facilities. Includes domestic and international registration documentation support.

Quantifiable outcome

• Successfully passed US FDA cGMP inspection with NAI (zero defects) for the 5th consecutive time in 2025
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core, minor and moderate.

• Brazilian National Health Surveillance Agency (巴西国家卫生监督局/ANVISA)coreOthers · 1 January 2024Brazilian ANVISA conducted on-site GMP inspection of the company's 11 APIs including aceclofenac, apixaban, celecoxib, crisaborole, febuxostat, vonoprazan fumarate, gabapentin, mirabegron, rivaroxaban, ticagrelor, and vildagliptin. All 11 passed the inspection, enabling market entry in Brazil.
• Zhejiang University of Technology Alumni Network (浙江工业大学校友网络)minorStrategic or Co-development Partner · 23 May 2023Zhejiang University of Technology Cooperation Development Department and Jiangxi Alumni Association visited the company. Led by Chairman Pang Zhengwei (Class of 1984 alumnus) and Vice President Huang Guojun (Class of 1984 alumnus), discussions focused on alumni resource sharing and establishing regular cooperation channels.
• Zhejiang University of Technology (浙江工业大学)moderateStrategic or Co-development Partner · 7 September 2019Zhejiang University of Technology delegation visited the company in September 2019 for technical exchange and industry-academia-research collaboration discussions. The company has engaged in multiple R&D cooperation projects with the university.
• Nanchang University (南昌大学)minorStrategic or Co-development Partner · 7 September 2019Nanchang University College of Chemistry and Chemical Engineering students and faculty visited the company for industry-academia exchange and collaboration.
• Jiangxi University of Science and Technology (江西理工大学)minorStrategic or Co-development Partner · 7 September 2019Pharmaceutical College of Jiangxi University of Science and Technology organized student visits for learning purposes.
• Nanchang University (南昌大学)minorStrategic or Co-development Partner · 3 July 2019Nanchang University delegation visited the company led by Chen Yiwang, Dean of the College of Chemical Engineering, to discuss industry-academia collaboration and student placement opportunities.
• Jiangxi University of Traditional Chinese Medicine (江西中医药大学)moderateStrategic or Co-development Partner · 1 January 2019In 2019, the company joined with Jiangxi University of Traditional Chinese Medicine and 9 other provincial pharmaceutical companies to establish the 'Jiangxi Province Traditional Chinese Medicine Industry Industry-Education Integration Strategic Alliance' (江西省中医药产业产教融合战略联盟), supporting collaborative innovation in the TCM pharmaceutical sector.
• Jiangxi Normal University (江西师范大学)moderateStrategic or Co-development Partner · 1 January 2018In 2018, the company and Jiangxi Normal University jointly established the 'Jiangxi Province New Drug R&D and Industry-Education Integration Key Innovation Center' (江西省新药研发产教融合重点创新中心), focusing on collaborative research in pharmaceutical development and industry-education integration.

Scale indicators7 records

Recent moves12 records

Expansion highlights5 records

Direct peers

• Zhejiang Huahai Pharmaceutical (华海药业): Vertically integrated Chinese API and finished-dose manufacturer with extensive FDA approvals and DMFs. Competes directly in CNS (Gabapentin area) and cardiovascular generic APIs for global markets.
• Asymchem Laboratories (凯莱英医药): Leading Chinese CDMO serving global innovative pharma with API and intermediates manufacturing. Direct competitor in CMO/CDMO services with comparable FDA-inspected facilities and advanced synthesis capabilities.
• Nhwa Pharmaceutical (恩华药业): Chinese pharmaceutical company specializing in CNS APIs including Gabapentin. Directly competes with Jiangxi Synergy in Gabapentin manufacturing and exports to regulated markets.
• Apeloa Pharmaceutical (普洛药业): Chinese API and intermediates manufacturer with FDA/EU GMP-certified facilities serving global pharmaceutical customers. Direct peer in small-molecule API manufacturing and CMO/CDMO services.
• Shandong Xinhua Pharmaceutical (新华制药): One of China's largest API manufacturers with FDA/EU GMP certifications and significant exports to developed markets. Comparable in scale, regulatory footprint, and specialty API portfolio.
• Porton Pharma Solutions (博腾股份): Chinese CDMO focused on small-molecule API development and manufacturing for global pharma. Comparable in serving international customers with FDA-inspected GMP facilities and similar therapeutic-area API exposure.

Broad incumbents

• WuXi AppTec (药明康德): Largest Chinese CRO/CDMO serving global pharma with API development and manufacturing capabilities. Competes in the broader CMO/CDMO space where Jiangxi Synergy operates.
• Northeast Pharmaceutical Group (东北制药): Large Chinese API manufacturer with broad therapeutic-area portfolio and established international customer base. Comparable in API manufacturing with overlapping product categories.
• Zhejiang Medicines & Health Products (浙江医药): Diversified Chinese pharmaceutical company with API, intermediates, and finished-dose operations. Larger scale player with overlapping API capabilities and global regulatory certifications.

Regional players

• Divis Laboratories (印度Divis): Indian API manufacturer and CDMO serving global pharma with FDA-inspected facilities. Primary international competitor to Chinese API manufacturers in regulated markets, particularly for generic APIs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/jiangxi-synergy-pharmaceutical-co-ltd-

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jiangxi Synergy Pharmaceutical